INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: INCB18424 (Ruxolitinib) may stop the growth of cancer cells by blocking some of
the enzymes needed for cell growth.
PURPOSE: This phase 1 clinical trial is studying the side effects and best dose of INCB18424
in treating young patients with relapsed or refractory solid tumor, leukemia, or
myeloproliferative disease.